Healius Limited

Equities

HLS

AU0000033359

Healthcare Facilities & Services

Market Closed - Australian S.E. Other stock markets 02:10:52 2024-04-24 am EDT			5-day change	1st Jan Change
1.25 ^AUD	-1.19%		+3.73%	-23.55%

Mar. 06	Morgan Stanley Adjusts Healius’ Price Target to AU$1 From AU$1.30, Keeps at Underweight	MT
Mar. 05	Australia shares inch lower as miners weigh; GDP data in focus	RE

Tranche Update on Healius Limited's Equity Buyback Plan announced on December 9, 2020.

November 30, 2021 at 04:14 pm EST

From January 1, 2021 to December 1, 2021, the company has repurchased 44,076,494 shares, representing 7.08% for AUD 199.1 million. With this, the company has completed the repurchase of 44,327,494 shares, representing 7.12% for AUD 200 million under the buyback announced on December 9, 2020.

Latest news about Healius Limited

Morgan Stanley Adjusts Healius’ Price Target to AU$1 From AU$1.30, Keeps at Underweight	Mar. 05	MT
Australia shares inch lower as miners weigh; GDP data in focus	Mar. 04	RE
Jarden Research Adjusts Healius’ Price Target to AU$1.26 From AU$1.29, Keeps at Underweight	Feb. 27	MT
Australian Shares Inch Up as Market Awaits Economic Data, US Fed Statements	Feb. 27	MT
Healius Shares Sink 6%; Reports 2% Decline in H1 FY24 Revenue, Widens Net Loss	Feb. 26	MT
Healius Limited Provides Earnings Guidance for Second Half of 2024 and Fiscal Year 2024	Feb. 26	CI
Transcript : Healius Limited, H1 2024 Earnings Call, Feb 27, 2024	Feb. 26
Healius Reports 2% Decline in H1 FY24 Revenue, Widens Net Loss	Feb. 26	MT
Healius Reports Wider H1 FY24 Loss as Revenue Slips 2%	Feb. 26	MT
Healius Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 26	CI
Healius Subsidiary Enters Commercial Deal with Geneva-based SGS	Feb. 06	MT
Australian shares on three-day winning streak; banks, miners lead	Jan. 23	RE
Australia shares starts 2024 higher on rate-cut hopes	Jan. 01	RE
Australian Clinical Labs Gets Regulator Approval to Withdraw Healius Takeover Offer	Dec. 26	MT
Australian Clinical Labs Limited cancelled the acquisition of Healius Limited from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.	Dec. 21	CI
Australian shares end higher on miners, Fed rate pivot	Dec. 15	RE
US Fed's Dovish Stance Lifts Australian Shares	Dec. 15	MT
Australian Clinical Labs Intends to Withdraw Proposed Healius Takeover	Dec. 14	MT
Competition Regulator Denies Australian Clinical Labs’ Proposed Takeover of Healius	Dec. 14	MT
Australia shares hit over 4-mth high on boost from commodities, banks stocks	Dec. 14	RE
Australian Clinical Labs to withdraw $1 billion offer for Healius; stocks fall	Dec. 14	RE
Healius Limited Appoints Ravi Jeyaraj as Director	Nov. 29	CI
Transcript : Healius Limited - Shareholder/Analyst Call	Nov. 27
Healius Limited Announces Chair Changes	Nov. 26	CI
Transcript : Healius Limited, Q1 2024 Sales/ Trading Statement Call, Nov 23, 2023	Nov. 22

Chart Healius Limited

Duration

Period

More charts

Company Profile

Healius Limited is an Australia-based healthcare company. The Company operates through two segments: Pathology and Imaging. The Pathology segment is a provider of pathology services, including specialty pathology and clinical trials. The Imaging segment is a provider of imaging and scanning services at standalone imaging sites, hospitals, and medical centers. The Company has a network of pathology laboratories, collection centers, and diagnostic imaging centers. It provides specialty diagnostic services to consumers and their referring practitioners. The Companyâs brands include Laverty Pathology, QML Pathology, Dorevitch Pathology, Western Diagnostic Pathology, Genomic Diagnostics, Abbott Pathology, IQ Pathology, Vetnostics, TML Vetnostics, Agilex Biolabs, Lumus Imaging, and others. The Company provides healthcare services that are accessible and efficient while supporting the coordination and continuity of quality patient care.

Sector

Healthcare Facilities & Services

Calendar

2024-08-20 - Q4 2024 Earnings Release (Projected)

Related indices

S&P/ASX 200

More about the company

Income Statement Evolution

More financial data

Ratings for Healius Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

1.25 AUD

Average target price

1.364 AUD

Spread / Average Target

+9.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
HEALIUS LIMITED	-23.55%	589M
SONIC HEALTHCARE LIMITED	-16.65%	8.34B
RADNET, INC.	+39.26%	3.59B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-32.64%	2.75B
SYNLAB AG	-8.06%	2.48B
DR. LAL PATHLABS LIMITED	-9.58%	2.32B
NEOGENOMICS, INC.	-15.20%	1.79B
FLEURY S.A.	-19.18%	1.54B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.19%	1.21B
METROPOLIS HEALTHCARE LIMITED	+5.57%	1.13B

Medical & Diagnostic Laboratories